These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 31745977)

  • 1. The GEF-H1/PKD3 signaling pathway promotes the maintenance of triple-negative breast cancer stem cells.
    Lieb WS; Lungu C; Tamas R; Berreth H; Rathert P; Storz P; Olayioye MA; Hausser A
    Int J Cancer; 2020 Jun; 146(12):3423-3434. PubMed ID: 31745977
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-cell growth and anti-cancer stem cell activities of the non-canonical hedgehog inhibitor GANT61 in triple-negative breast cancer cells.
    Koike Y; Ohta Y; Saitoh W; Yamashita T; Kanomata N; Moriya T; Kurebayashi J
    Breast Cancer; 2017 Sep; 24(5):683-693. PubMed ID: 28144905
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined inhibition of JAK2-STAT3 and SMO-GLI1/tGLI1 pathways suppresses breast cancer stem cells, tumor growth, and metastasis.
    Doheny D; Sirkisoon S; Carpenter RL; Aguayo NR; Regua AT; Anguelov M; Manore SG; Arrigo A; Jalboush SA; Wong GL; Yu Y; Wagner CJ; Chan M; Ruiz J; Thomas A; Strowd R; Lin J; Lo HW
    Oncogene; 2020 Oct; 39(42):6589-6605. PubMed ID: 32929154
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Truncated HDAC9 identified by integrated genome-wide screen as the key modulator for paclitaxel resistance in triple-negative breast cancer.
    Lian B; Pei YC; Jiang YZ; Xue MZ; Li DQ; Li XG; Zheng YZ; Liu XY; Qiao F; Sun WL; Ling H; He M; Yao L; Hu X; Shao ZM
    Theranostics; 2020; 10(24):11092-11109. PubMed ID: 33042272
    [No Abstract]   [Full Text] [Related]  

  • 5. Simultaneous CK2/TNIK/DYRK1 inhibition by 108600 suppresses triple negative breast cancer stem cells and chemotherapy-resistant disease.
    Sato K; Padgaonkar AA; Baker SJ; Cosenza SC; Rechkoblit O; Subbaiah DRCV; Domingo-Domenech J; Bartkowski A; Port ER; Aggarwal AK; Ramana Reddy MV; Irie HY; Reddy EP
    Nat Commun; 2021 Aug; 12(1):4671. PubMed ID: 34344863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combination of monensin and erlotinib synergistically inhibited the growth and cancer stem cell properties of triple-negative breast cancer by simultaneously inhibiting EGFR and PI3K signaling pathways.
    Fang T; Hu S; Song X; Wang J; Zuo R; Yun S; Jiang S; Guo D
    Breast Cancer Res Treat; 2024 Sep; 207(2):435-451. PubMed ID: 38958784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sulforaphane enhances the anticancer activity of taxanes against triple negative breast cancer by killing cancer stem cells.
    Burnett JP; Lim G; Li Y; Shah RB; Lim R; Paholak HJ; McDermott SP; Sun L; Tsume Y; Bai S; Wicha MS; Sun D; Zhang T
    Cancer Lett; 2017 May; 394():52-64. PubMed ID: 28254410
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The bromodomain inhibitor OTX015 (MK-8628) exerts anti-tumor activity in triple-negative breast cancer models as single agent and in combination with everolimus.
    Vázquez R; Riveiro ME; Astorgues-Xerri L; Odore E; Rezai K; Erba E; Panini N; Rinaldi A; Kwee I; Beltrame L; Bekradda M; Cvitkovic E; Bertoni F; Frapolli R; D'Incalci M
    Oncotarget; 2017 Jan; 8(5):7598-7613. PubMed ID: 27935867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IRE1α inhibitor enhances paclitaxel sensitivity of triple-negative breast cancer cells.
    Wu M; Zhang L; Pi L; Liu L; Wang S; Wu Y; Pan H; Liu M; Yi Z
    Cell Oncol (Dordr); 2024 Oct; 47(5):1797-1809. PubMed ID: 38888849
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Peptide-Targeted High-Density Lipoprotein Nanoparticles for Combinatorial Treatment against Metastatic Breast Cancer.
    Jiang C; Wang X; Teng B; Wang Z; Li F; Zhao Y; Guo Y; Zeng Q
    ACS Appl Mater Interfaces; 2021 Aug; 13(30):35248-35265. PubMed ID: 34284582
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models.
    Guo Z; Luo J; Mashl RJ; Hoog J; Maiti P; Fettig N; Davies SR; Aft R; Held JM; Govindan R; Ding L; Li S; von Morze C; Wulf GM; Shoghi KI; Ma CX
    Cancer Res Commun; 2024 Jun; 4(6):1430-1440. PubMed ID: 38717161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
    Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
    Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advancing targeted combination chemotherapy in triple negative breast cancer: nucleolin aptamer-mediated controlled drug release.
    Ma Y; Xie D; Chen Z; Shen X; Wu X; Ding F; Ding S; Pan Y; Li F; Lu A; Zhang G
    J Transl Med; 2024 Jul; 22(1):604. PubMed ID: 38951906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of the TrkA and JAK2 pathways using entrectinib and pacritinib suppresses the growth and metastasis of HER2-positive and triple-negative breast cancers.
    Regua AT; Bindal S; Najjar MK; Zhuang C; Khan M; Arrigo ABJ; Gonzalez AO; Zhang XR; Zhu JJ; Watabe K; Lo HW
    Cancer Lett; 2024 Aug; 597():217023. PubMed ID: 38852701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo.
    Yu F; Zhao J; Hu Y; Zhou Y; Guo R; Bai J; Zhang S; Zhang H; Zhang J
    Oncol Rep; 2016 Jul; 36(1):356-64. PubMed ID: 27175939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
    Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
    Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.
    Borges S; Perez EA; Thompson EA; Radisky DC; Geiger XJ; Storz P
    Mol Cancer Ther; 2015 Jun; 14(6):1306-16. PubMed ID: 25852060
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of RPTOR overcomes resistance to EGFR inhibition in triple-negative breast cancer cells.
    You KS; Yi YW; Kwak SJ; Seong YS
    Int J Oncol; 2018 Mar; 52(3):828-840. PubMed ID: 29344641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.
    Dávila-González D; Choi DS; Rosato RR; Granados-Principal SM; Kuhn JG; Li WF; Qian W; Chen W; Kozielski AJ; Wong H; Dave B; Chang JC
    Clin Cancer Res; 2018 Mar; 24(5):1152-1162. PubMed ID: 29301832
    [No Abstract]   [Full Text] [Related]  

  • 20. Signaling pathway inhibitors target breast cancer stem cells in triple-negative breast cancer.
    Li W; Yang H; Li X; Han L; Xu N; Shi A
    Oncol Rep; 2019 Jan; 41(1):437-446. PubMed ID: 30365081
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.